Sellas Life Sciences Group Inc (SLS) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Sellas Life Sciences Group Inc stock forecast from 0 analysts, the average analyst target price for Sellas Life Sciences Group Inc is not available over the next 12 months. Sellas Life Sciences Group Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Sellas Life Sciences Group Inc is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, Sellas Life Sciences Group Inc’s stock price was USD 1.27. Sellas Life Sciences Group Inc’s stock price has changed by -3.79% over the past week, +11.40% over the past month and +43.50% over the last year.
No recent analyst target price found for Sellas Life Sciences Group Inc
No recent average analyst rating found for Sellas Life Sciences Group Inc
Company Overview Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. Read Less
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeu...Read More
Frequently Asked Questions About Sellas Life Sciences Group Inc (SLS) Stock
Stock Target Advisor's fundamental analysis for Sellas Life Sciences Group Inc's stock is Very Bearish.
Unfortunately we do not have enough data on SLS's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on SLS's stock to indicate what its average analyst target is.
SLS stock's Price/Earning ratio is 3.37.
Our analysis grades SLS stock's Price / Earning ratio at F. This means that SLS stock's Price/Earning ratio is above 43.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this SLS may be fairly valued for its sector
The last closing price of SLS's stock was USD 1.27.
The most recent market capitalization for SLS is USD 0.11B.
Unfortunately we do not have enough analyst data on SLS's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Sellas Life Sciences Group Inc's stock.
As per our most recent records Sellas Life Sciences Group Inc has 16 Employees.
Sellas Life Sciences Group Inc's registered address is Times Square Tower, New York, NY, United States, 10036.
You can get more information about it from Sellas Life Sciences Group Inc's website at https://www.sellaslifesciences.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Sellas Life Sciences Group Inc (SLS) Stock
Stock Target Advisor's fundamental analysis for Sellas Life Sciences Group Inc's stock is Very Bearish.
Unfortunately we do not have enough data on SLS's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on SLS's stock to indicate what its average analyst target is.
SLS stock's Price/Earning ratio is 3.37.
Our analysis grades SLS stock's Price / Earning ratio at F. This means that SLS stock's Price/Earning ratio is above 43.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this SLS may be fairly valued for its sector
The last closing price of SLS's stock was USD 1.27.
The most recent market capitalization for SLS is USD 0.11B.
Unfortunately we do not have enough analyst data on SLS's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Sellas Life Sciences Group Inc's stock.
As per our most recent records Sellas Life Sciences Group Inc has 16 Employees.
Sellas Life Sciences Group Inc's registered address is Times Square Tower, New York, NY, United States, 10036.
You can get more information about it from Sellas Life Sciences Group Inc's website at https://www.sellaslifesciences.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SLS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
